Retrospective analysis of the frequency of centrofacial telangiectasia in systemic sclerosis patients treated with bosentan or ilomedin

BACKGROUND: Bosentan is a dual endothelin receptor antagonist initially introduced for the treatment of pulmonary arterial hypertension and recently approved for the treatment of digital ulcers in patients with systemic sclerosis (SSc). Our clinical observations indicate that bosentan therapy may be...

Descripción completa

Detalles Bibliográficos
Autores principales: Hetzer, Sonja, Buhren, Bettina Alexandra, Schrumpf, Holger, Bölke, Edwin, Meller, Stephan, Kammers, Kai, Gerber, Peter Arne, Homey, Bernhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902062/
https://www.ncbi.nlm.nih.gov/pubmed/24410934
http://dx.doi.org/10.1186/2047-783X-19-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902062/
https://www.ncbi.nlm.nih.gov/pubmed/24410934
http://dx.doi.org/10.1186/2047-783X-19-2

Ejemplares similares